TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief Financial Officer, effective September 21, 2026.

TransMedics is reiterating its full-year 2026 revenue guidance of $737 million to $757 million, representing approximately 22% to 25% year-over-year growth. This guidance continues to exclude any revenue contribution from the Company's recent strategic investment in PAD Aviation Service GmbH. The Company expects to revisit this outlook in conjunction with its third quarter 2026 results.